New hemostatic powder technology: immediate hemostasis, low rebleeding rates, and minimal scattering or catheter clogging.

  • A proprietary powder coating technology that minimizes catheter clogging and particle scattering 
  • Unique delivery system that doesn’t rely on CO2 or air compressors
  • Distinctive blue color so you can have the confidence the lesion is fully covered
  • Highly adhesive gel that reacts to moisture, not just active bleeding, so it can be used in a variety of clinical applications

View Nexpowder™ info sheet

View Info Sheet

NexpowderTM* Endoscopic Hemostasis System Clinical Summary

A prospective study assessed the feasibility of Nexpowder™* application in refractory upper gastrointestinal bleeding in 17 patients, and has shown:

  • Successful application in all patients
  • Initial hemostasis in 16 out of 17 patients: 94%.
  • Rebleeding within 30 days was seen in 3 out of 16 patients (19%)
  • Remnants of the gel was evident in 11 out of 16 patients (69%) at the second examination after 24 hours1

In a retrospective study in Korea monotherapy with Nexpowder™* was administered to 56 patients with active bleeding. Immediate hemostasis was achieved in 96.4% (54/56) with a rebleeding rate of 3.7% (2/54) and no adverse events.3

Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding

Jongbeom Shin et al. 

Published in: BMC Gastroenterol (2021) 21:40

Conclusion: In conclusion, this single-arm study demonstrated Nexpowder™* was associated with excellent immediate hemostasis rate and safety profile as well as low rebleeding for upper GI tumor bleeding.

New hemostatic powder technology

Immediate hemostasis. Low rebleeding rates. Minimal scattering or catheter clogging. Learn more about our Nexpowder™* Endoscopic hemostasis system

Visit GI HUB

Visit our GI HUB to learn more about our portfolio and healthcare solutions

Contact us

Contact us to learn more about the clinical and patient benefits of the Nexpowder™* Endoscopic hemostasis system.
  • ™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company

  • 1. Antunes C, Copelin II EL. Upper Gastrointestinal Bleeding. [Updated 2019 Sep 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470300/

  • 2. Raphaeli T, Menon R. Current treatment of lower gastrointestinal hemorrhage. Clin Colon Rectal Surg. 2012;25(4):219-227. doi:10.1055/s-0032-1329393

  • 3. Park JS, Kim HK, Shin YW, et al. Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding. Endosc Int Open. 2019 Dec; 7(12):E1763-E1767.

  • 4. Park JS, Bang BW, Hong SJ, et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy. 2019 May; 51(5):458-462.

  • 5. Bang B, Lee E, Maeng J, et al. Efficacy of a novel endoscopically deliverable muco-adhesive hemostatic powder in an acute gastric bleeding porcine model. PLoS One. 2019 Jun 11; 14(6):e0216829.